February 16, 2023 | From the Trenches
As I ride the Amtrak towards New York City for a series of meetings on Park Avenue with bankers/analysts, face-to-face (F2F) meetings are back as part of my normal routine.
By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC
December 13, 2022 | LifeSciVC
Today we’re thrilled to announce the acquisition of Nimbus’ allosteric Tyk2 autoimmune program by Takeda for up to $6 billion in an upfront and future milestones.
July 27, 2022 | From the Trenches
From academic research, patent law, business development, to being a CEO, all my experiences have taught me two things. First, one cannot do it all alone (especially in biotech). Second, the biotech ecosystem is unique in a sense that everyone, irrespective of background, shares the same goal: to improve patient lives.
By Ivana Magovcevic-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC
July 6, 2022 | LifeSciVC
It’s biotech armageddon out there: with massive value destruction across public stocks, it’s clearly the worst market backdrop in over 20 years.
June 29, 2022 | Uncategorized
Biotech venture creation is a team endeavor. We work with the best teams in the business. Meet some of our new CEOs and the most recent additions to our investment team in our newsletter.